The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
IGA score for patients with melasma or post-acne post-inflammatory hyperpigmentation (PIHP)
Timeframe: from baseline to Day84
modified Melasma Area Severity Index (mMASI) for patients with melasma
Timeframe: from baseline to Day 84
Post-Acne Hyper Pigmentation Index (PAHPI)
Timeframe: from baseline to Day 84
solar lentigo pigmentation scale
Timeframe: from baseline to Day84